Swiss Group for Clinical Cancer Research (SAKK)
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J 2023; 13:93.
19.06.2023Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
19.06.2023Blood Cancer J 2023; 13:93
Hilberink Jacobien R, van Zeventer Isabelle A, Chitu Dana A, Pabst Thomas, Klein Saskia K, Stussi Georg, Griskevicius Laimonas, Valk Peter J M, Cloos Jacqueline, van de Loosdrecht Arjan A, Breems Dimitri A, van Lammeren-Venema Daniëlle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W M, Legdeur Marie-Cecile J C, Tick Lidwine W, Chalandon Yves, Ammatuna Emanuele, Blum Sabine, Löwenberg Bob, Ossenkoppele Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls Gerwin
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
27.04.2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
27.04.2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
12.07.2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
12.07.2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol 2021; 80:306-315.
14.06.2021Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
14.06.2021Eur Urol 2021; 80:306-315
Ghadjar Pirus, Zaugg Kathrin, Guckenberger Matthias, Ost Piet, Reuter Christiane, Bosetti Davide G, Kaouthar Khanfir, Gomez Silvia, Wust Peter, Thalmann George N, Aebersold Daniel M, Sumila Marcin, Schär Corinne, Hayoz Stefanie, Bernhard Jürg, Zwahlen Daniel R, Hölscher Tobias, Gut Philipp, Polat Bülent, Hildebrandt Guido, Müller Arndt-Christian, Plasswilm Ludwig, Papachristofilou Alexandros, Swiss Group for Clinical Cancer Research (SAKK)
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
25.04.2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
25.04.2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
Barbier M, Pardo E, Panje C, Gautschi O, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ 2021; 22:669-677.
21.03.2021A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
21.03.2021Eur J Health Econ 2021; 22:669-677
Barbier Michaela Carla, Pardo Esther, Panje Cédric, Gautschi Oliver, Lupatsch Judith Eva, Swiss Group for Clinical Cancer Research (SAKK)
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
01.11.2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
01.11.2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Panje C, Schwenkglenks M, Gautschi O, Plasswilm L, Aebersold D, Dedes K, Lorez M, Pardo E, Barbier M, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol 2020; 31:501-506.
16.01.2020A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
16.01.2020Ann Oncol 2020; 31:501-506
Panje Cédric, Schwenkglenks M, Gautschi O, Plasswilm Ludwig, Aebersold D M, Dedes K J, Lorez M, Pardo E, Barbier M, Lupatsch J E, Swiss Group for Clinical Cancer Research (SAKK)
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Metaxas Y, von Moos R, Rauch D, Appenzeller C, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G, Zucali P, Pless M, Grosso F, Eboulet E, Früh M, Swiss Group for Clinical Cancer Research (SAKK). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Ann Oncol 2020; 31:495-500.
16.01.2020Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
16.01.2020Ann Oncol 2020; 31:495-500
Metaxas Y, von Moos R, Rauch D, Appenzeller Christina, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G L, Zucali P A, Pless M, Grosso F, Eboulet E I, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol 2019; 14:166.
11.09.2019Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
11.09.2019Radiat Oncol 2019; 14:166
Panje Cédric, Plasswilm Ludwig, Ruhstaller Thomas, Gerard Marie-Aline, Hawle Hanne, Schacher Sabina, Henke Guido, Meier Urs R, Garcia Schüler Helena, Herrmann Evelyn, Baracos Vickie E, Hayoz Stefanie, Höng Laura, Swiss Group for Clinical Cancer Research (SAKK)
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial
Riesterer O, Krayenbuehl J, Weder W, Sabrina Stark L, Zimmermann F, Nackaerts K, Zwahlen D, Mahmut Ozsahin E, Plasswilm L, Aebersold D, Xyrafas A, Stahel R, Ciernik I, Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol 2019; 138:121-125.
25.06.2019Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial
25.06.2019Radiother Oncol 2019; 138:121-125
Riesterer Oliver, Krayenbuehl Jerome, Weder Walter, Sabrina Stark L, Zimmermann Frank, Nackaerts Kristiaan, Zwahlen Daniel R, Mahmut Ozsahin E, Plasswilm Ludwig, Aebersold Daniel M, Xyrafas Alexandros, Stahel Rolf A, Ciernik I Frank, Swiss Group for Clinical Cancer Research (SAKK)
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol 2018; 129:257-263.
10.08.2018A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
10.08.2018Radiother Oncol 2018; 129:257-263
Panje Cédric, Lupatsch Judith E, Plasswilm Ludwig, Aebersold Daniel M, Siano Marco, Gautschi Oliver, Schwenkglenks Matthias, Matter-Walstra Klazien, Dedes Konstantin J, Swiss Group for Clinical Cancer Research (SAKK)
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
Weber W, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal S, Ruhstaller T, Fehr P, Knauer M, Pioch V, Güth U, Hess T, Tausch C, Hayoz S, Fehr M, Ribi K, Hawle H, Lupatsch J, Matter-Walstra K, Chiesa F, Dedes K, Berclaz G, Lelièvre L, Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. Ann Surg Oncol 2018; 25:2632-2640.
08.06.2018Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
08.06.2018Ann Surg Oncol 2018; 25:2632-2640
Weber Walter Paul, Sarlos Dimitri, Leo Cornelia, Canonica Claudia, Gabriel Natalie, Zeindler Jasmin, Cassoly Estelle, Andrieu Christiane, Soysal Savas Deniz, Ruhstaller Thomas, Fehr Peter Martin, Knauer Michael, Pioch Verena, Güth Uwe, Hess Thomas, Tausch Christoph, Hayoz Stefanie, Fehr Mathias Konrad, Ribi Karin, Hawle Hanne, Lupatsch Judith Eva, Matter-Walstra Klazien, Chiesa Federica, Dedes Konstantin Johannes, Berclaz Gilles, Lelièvre Loic, Swiss Group for Clinical Cancer Research (SAKK)
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
11.12.2017Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
11.12.2017Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
Ghadjar P, Thalmann G, Aebersold D, Wust P, Biaggi Rudolf C, Dal Pra A, Schär C, Papachristofilou A, Putora P, Müller A, Hildebrandt G, Polat B, Gut P, Hölscher T, Stein J, Zwahlen D, Bernhard J, Hayoz S, Swiss Group for Clinical Cancer Research (SAKK). Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiother Oncol 2017
03.11.2017Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
03.11.2017Radiother Oncol 2017
Ghadjar Pirus, Thalmann George N, Aebersold Daniel M, Wust Peter, Biaggi Rudolf Christine, Dal Pra Alan, Schär Corinne, Papachristofilou Alexandros, Putora Paul Martin, Müller Arndt-Christian, Hildebrandt Guido, Polat Bülent, Gut Philipp, Hölscher Tobias, Stein Jürgen, Zwahlen Daniel R, Bernhard Jürg, Hayoz Stefanie, Swiss Group for Clinical Cancer Research (SAKK)
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Steffen T, Ruhstaller T, Brauchli P, Thierstein S, Schiesser M, Gloor B, Furrer M, Marti W, Huber O, Kettelhack C, Schnider A, Dietrich D, Swiss Group for Clinical Cancer Research (SAKK). Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. Ann Surg 2017; 269:83-87.
24.07.2017Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
24.07.2017Ann Surg 2017; 269:83-87
Steffen Thomas, Ruhstaller Thomas, Brauchli Peter, Thierstein Sandra, Schiesser Marc, Gloor Beat, Furrer Markus, Marti Walter R, Huber Olivier, Kettelhack Christoph, Schnider Annelies, Dietrich Daniel, Swiss Group for Clinical Cancer Research (SAKK)
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
20.03.2017Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
20.03.2017Invest New Drugs 2017; 35:766-772
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C V, Allegrini S, Ackermann C J, Mark M, Jörger Markus, Griguolo G, Homicsko K, von Moos R, Hess Dagmar, Swiss Group for Clinical Cancer Research (SAKK)
Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer
Ghadjar P, Kranzbühler H, Najafi Y, Ost P, Azinwi N, Reuter C, Bodis S, Kaouthar K, Budach V, Aebersold D, Thalmann G, Sumila M, Biaggi-Rudolf C, Stalder L, Hayoz S, Genitsch V, Zwahlen D, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller A, Putora P, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. BJU Int 2017; 120:E45-E51.
19.01.2017Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer
19.01.2017BJU Int 2017; 120:E45-E51
Ghadjar Pirus, Kranzbühler Helmut, Najafi Yousef, Ost Piet, Azinwi Ngwa C, Reuter Christiane, Bodis Stephan, Kaouthar Khanfir, Budach Volker, Aebersold Daniel M, Thalmann George N, Sumila Marcin, Biaggi-Rudolf Christine, Stalder Lukas, Hayoz Stefanie, Genitsch Vera, Zwahlen Daniel R, Hölscher Tobias, Gut Philipp, Guckenberger Matthias, Hildebrandt Guido, Müller Arndt-Christian, Putora Paul Martin, Papachristofilou Alexandros, Swiss Group for Clinical Cancer Research (SAKK)
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015
08.12.2015The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
08.12.2015Ann Oncol 2015
Strasser Florian, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK)
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25.
27.06.2014Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
27.06.2014Breast 2014; 23:511-25
Rordorf Tamara, Hassan Azza Adel, Azim Hamdy, Alexandru Eniu, Er Ozlem, Gokmen Erhan, Güral Zeynep, Mardiak Jozef, Minchev Velko, Peintinger Florentia, Szendroi Miklos, Takac Itzok, Tesarova Petra, Vorobiof Daniel, Vrbanec Damir, Yildiz Ramazan, Yücel Serap, Zekri Jamal, Oyan Basak, Swiss Group for Clinical Cancer Research (SAKK)